Dra. Ana Malvar

Especialidad: Nefrología
País: Argentina

Educación superior y especialidad:

  • UBA
  • Especialista en Nefrologia y Medio Interno

Experiencia laboral:

  • Medica de Planta del Hospital Fernandez
  • Investigadora Principal de la organización medica de Investigacion
  • Directora de la carrera de especialistas en nefrología de la UBA

Asociaciones:

  • Soc Arg de Nefrologia
  • Soc Intenacional de Nefrologia
  • Lupus Trial network
  • KDIGO Comite
  • GLADEL

Distinciones y publicaciones:

  1. Malvar A., Lococo B., et al. Crescentic Glomerulonephrities; 5 classes. Nefrología Dialisis y Transplante, vol 3, June 2002, 3:15-19
  2. Malvar A., Lococo B., et al. Lupus Nephritis in patients with HIV. Nefrología Dialisis y Transplante,vol 25 , June 2005, 2:65-68
  3. Quevedo A, Malvar A., et al. IgA Nephropathy. Nefrología Diálisis y Transplante, vol 28, 2008, 2:79-81
  4. Nadal M., Malvar A. et al. Use of enteric coated mycophenolate sodium in adults resistant nephrotic syndrome, Clinical Nephology vol 79, 2013:6:439-444.
  5. Alvarado A., Malvar A., et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus, 2014, 23:840-847.
  6. Malvar A., Rovin BH, et al. Histologic versus Clinical remission in proliferative Lupus Nephritis. Nephrol Dial Transplant (2015).
  7. Parikh SV, Malvar A, et al. Characterizing the Immune profile of the kidney biopsy at Lupus Nephritis flare differentiates early treatment responders from non-responders. Lupus Science and Medicine, 2015.
  8. Nishi R, Malvar A., et al. Fc RIIA-driven lupus nephritis is averted by Bcr-JCI-RG-1. Journal Clinical Investigation, 2015
  9. SV, Malvar A. The Kidney Biopsy in Lupus Nephritis: Past, Present, and Future. Seminars in Nephrology, 2015
  10. SV, Malvar A. Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. al. Lupus Science & Medicine Nov 2015;2: e000112. doi:10.1136
  11. Tais R, Malvar A. Proteinuria and Microhematuria in a patient with Systemic Scleroderma and ANCA Vasculitis. Nefrología Argentina. Vol. 2, number 3, 2016
  12. Lococo B, Malvar A et al. IgA Nephropathy: Therapeutic management of the IgA Gn, literature review. NDT Argentina, vol36, n2, 2016
  13. Ferrari M, Malvar A. Renal Amiliodosis AA. Nefrología Argentina. Vol. 15, number 4, 2017
  14. Trimarchi H, Malvar A, et al. Editor: Glomerulopathies Book. El Hipocampo, 1st edition, Buenos Aires , Argentina ,2017
  15. A Malvar, Rovin B, Alvarado A. Lupus Nephritis. Glomerulopathies, El Hipocampo, 1st ed., 581-606, 201.2017
  16. B Rovin, A Malvar. Reimagining the kidney biopsy in the era of diagnostic biomarkers of glomerular disease. K Int, vol 95:2,265-267,2019
  17. Management and treatment of glomerular disease: conclusions from KDIGO Controversies Conference. K Int, vol 95:2,268-280,2019
  18. Parikh S, Malvar A et al. Rethinking Lupus Nephritis Classification on a molecular level. Jour of Clin Med 8, 1524, 2019
  19. Standardized Outcomes in Nephrology-Glomerular Disease (Song –GD) establishing a core outcome set for trials in patients with glomerular disease. Kidney International, June 2019.
  20. Cassol C, Bot C , Malvar A et al. Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy. NDT, 2019
  21. Malvar A, Alberton V et al. Podocyte Infolding Glomerulopathy: first case in Latin America described. Nefrologia Española ,2020
  22. Malvar A, Alberton V et al. Kidney biopsy-managed of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. K Int, 2020
  23. B cell depletion and response in a randomized control trial of Obinutuzumab for proliferative Lupus Nephritis Conference Paper, European Lupus Meeting, March 2020
  24. A Malvar, V Alberton et al. Complementing the diagnosis with the patient s eyes. Tubulo interstitial Nephritis and Uveitis (TINU) Syndrome. Rev Nefrol Dial Traspl.2020; 4146-149.
  25. Furie R, Rovin B, Houssieau F, Malvar A et al. Two years, randomized, controlled trial of belimumab in lupus nephritis. NEJM 2020,283:1117-1128Parikh S, Malvar A et al, A novel inflammatory Dendritic Cell that is abundant and contiguous to T cells in kidneys of patients with Lupus Nephritis. Front Immunol, Feb 2021
  26. Furie R, Aroca G, Malvar A et al.B cell depletion with Obinutuzumab for the treatment of proliferative lupus nephritis; a RCT, Ann Rheum Dis 2021 (2209020)
  27. Rovin B, Furie R, Malvar A et al. Effects of belimumab on kidney outcomes and preservation of kidney function. A secondary analysis of the BLISSLN trial. K Int vol 102 (403-413) 2022
  28. Malvar A, Alberton V, Rovin B. Chapter 27 Lupus Nephritis. Comprehensive Clinical Nephrology, Johnson MD ed Elsevier 7th edition, 2022.
  29. Parikh S, Malvar A et al Molecular profiling of kidney compartments from serial biopsies differentiates treatment responders from non-responders in lupus nephritis. K Int, Oct;102(4):845-865, 2022
  30. Amoura Z, Anders J Malvar A et al. Effects of Belimumab on renal outcomes in patients with relapses and newly diagnosed active lupus nephritis, Nephr and Ther, 2022 (07.170)
  31. Malvar a, Alberton V, Lococo et al. The trajectory of glomerular and tubulointerstitial lesions after treatment of lupus nefritis, Lupus Sci& Med (469-474) 2022
  32. Malvar A, Alberton V, Rovin B et al. Remission of lupus nephritis; the histological response in succefully treated lupus nephritis. Lupus Sci& Med (000932) May 2022
  33. Malvar A, Alberton V, Heguilen R et al. Repeat kidney biopsy findings of Lupus Nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus placebo. A “post-hoc” analysis of participants in the BLISS-LN study belonging to a single center. Lupus, Oct 2023 (1394-1401)
  34. Vital E, Tas W, malvar A et al. Longitudinal assessment of biomarkers in Nobility trial, Ann of Rheum Dis, 2024, EULAR
  35. Furie R, Terres, R, Malvar A, et al, Obinutuzumab benefits patients with active lupus nephritis, Ann of Rheum Dis, 2024, EULAR
  36. Serrano R, Morales R, malvar A et al. Pregnancy outcomes in sistemic SLE data from a multiethnic Latin-American cohort. Lupus Sci& Med ,2024
  37. Terreros P. Alberton V, Malvar A et al. Kidney sized by ultrasound: correlation between antropometric, renal, sclerosis and GFR. K Int reports, March 2024 WNC.
  38. Martinez J, Alberton V, malvar A et al. Pigment nephropathy in drummers, K Int reports, March 2024 WNC
  39. Alberton V, Malvar A, Rovin B et al. The chronicity index should be modified to exclude fibrous crescents. K Int reports, March 2024 WNC
  40. Rovin B, Furie R, Malvar A et al. Kidney outcomes and preservation of kidney function with Obinutuzumab in patients with lupus nephritis: a post Hoc Analysis of the Nobility. Arthitis Rheum Feb 2024(247-254)
  41. Frangou E, Bajema I, Malvar A et al. Immunosuppression withdrawal in patients with lupus nephritis. JASN 2024.
  42. Efficacy and Safety of Obinutuzumab in Active Lupus nephritis. Furie R, Rovin B, Malvar A et al. NEJM 2025
  43. Evolution of crescents in Lupus Nephritis. Malvar a et al. K Int feb 2025
  44. Parodis I, Malvar A et al. LNTN: repeat biopsy based definitions of treatment response. Autoimmunity Reviews 2025.
  45. Parodis I, Rovin B, Malvar A et al. Lupus Nephritis, Nature Reviews Disease Primers, in press
  46. Malvar A, Alberton V, Rovin B. Chapter 27: Lupus Nephritis. Comprehensive Clinical Nephrology, Johnson MD ed Elsevier 8th edition, in press
  47. Shen N, WeimannJ, Malvar A et al. Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebocontrolled, phase II study.Rheumatic & Musculoeskeletal Diseases, 2025

Videos

Facebook

Asociación Salvadoreña de Reumatología

Ubicanos en